Health News

Biomarker may help identify prostate cancer patients at increased risk of metastasis

 9 months ago       121 Views

For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent. Unfortunately, the remaining 10 percent of patients develop locally invasive and metastatic disease, which increases the severity of the disease and likelihood of death and limits treatment options. A report in The American Journal of Pathology indicates that a significantly lower presence of syntaphilin (SNPH)--a mitochondrial protein--within the tumor's central core versus at the tumor's invasive outer edge, may identify patients at increased risk of metastasis. These patients may require more rigorous testing, surveillance, and treatment.

"Predicting aggressive behavior in prostate cancer is an entirely unmet and urgent need. There are currently no tissue-based biomarkers to help clinicians reliably identify the subset of prostate cancer patients who will progress to life-threatening, disseminated disease and who would, therefore, benefit from systemic therapies before or following prostatectomy. If our findings are supported by larger studies, SNPH measurement in tumors could be developed into a predictive biomarker," explained Marie E. Robert, MD, of the Department of Pathology, Yale School of Medicine, New Haven, CT, USA.


Author: @DailyCupofYoga

Source: news-medical.net

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.